Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dexrazoxane Hydrochloride

FDA-approved product (injectable, injection), marketed as Dexrazoxane Hydrochloride, Totect, Zinecard.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Dexrazoxane Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Cardiomyopathy
  • Extravasation of Diagnostic and Therapeutic Materials

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Detoxifying agents for antineoplastic treatment
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Dexrazoxane Hydrochloride, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA25.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli25.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis35.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dexrazoxane Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dexrazoxane Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

    NCT07125183 · start 2026-12

    Registered record
    Registry ID
    NCT07125183
    Conditions
    Sarcoma
    Interventions
    Doxorubicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-12
    Completion
    2029-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma
    InterventionDoxorubicin
    PhasePhase 2
    Registry statusRecruiting

  • The CARDIOPROTECT Trial

    NCT07654426 · start 2026-08-31

    Registered record
    Registry ID
    NCT07654426
    Conditions
    Diffuse Large B-cell Lymphoma (DLBCL); Cardiotoxicity; Lymphoma
    Interventions
    Dexrazoxane; Dexrazoxane placebo; Doxorubicin; Liposomal Doxorubicin; Cyclophosphamide; Vincristine; Prednisone; Rituximab; Polatuzumab Vedotin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-08-31
    Completion
    2035-12-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiffuse Large B-cell Lymphoma (DLBCL); Cardiotoxicity; Lymphoma
    InterventionDexrazoxane; Dexrazoxane placebo; Doxorubicin; Liposomal Doxorubicin +5 more
    PhasePhase 2
    Registry statusRecruiting

  • Dexrazoxane to Protect Against Hemorrhagic STEMI

    NCT07502521 · start 2025-08-30

    Registered record
    Registry ID
    NCT07502521
    Conditions
    Acute Myocardial Infarction (AMI)
    Interventions
    Dexrazoxane; Normal Saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2025-08-30
    Completion
    2026-03-16
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myocardial Infarction (AMI)
    InterventionDexrazoxane; Normal Saline
    PhasePhase 2
    Registry statusCompleted

  • Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

    NCT06647953 · start 2025-03-21

    Registered record
    Registry ID
    NCT06647953
    Conditions
    Pleuropulmonary Blastoma
    Interventions
    Biospecimen Collection; Biospecimen Collection; Bone Scan; Computed Tomography; Cyclophosphamide; Dactinomycin; Dexrazoxane; Doxorubicin; Echocardiography Test; Ifosfamide; Magnetic Resonance Imaging; Multigated Acquisition Scan; Patient Observation; Positron Emission Tomography; Topotecan; Ultrasound Imaging; Vincristine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-03-21
    Completion
    2029-03-31
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPleuropulmonary Blastoma
    InterventionBiospecimen Collection; Biospecimen Collection; Bone Scan; Computed Tomography +13 more
    PhasePhase 3
    Registry statusRecruiting

  • Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma

    NCT06220032 · start 2024-08-15

    Registered record
    Registry ID
    NCT06220032
    Conditions
    DLBCL - Diffuse Large B Cell Lymphoma
    Interventions
    Dexrazoxane; Rituximab; Cyclophosphamide; Doxorubicin; Vincristine; Prednisolone; Lenalidomide; Pegfilgrastim
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-08-15
    Completion
    2028-12-15
    Enrolment
    324

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDLBCL - Diffuse Large B Cell Lymphoma
    InterventionDexrazoxane; Rituximab; Cyclophosphamide; Doxorubicin +4 more
    PhasePhase 3
    Registry statusRecruiting

  • CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients

    NCT06262438 · start 2024-02-06

    Registered record
    Registry ID
    NCT06262438
    Conditions
    Acute Myeloid Leukemia in Children
    Interventions
    Quizartinib; Etoposide; Dexrazoxane; Mitoxantrone; Cytarabine; Methotrexate; Daunorubicin; Fludarabine; allo-SCT
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-02-06
    Completion
    2032-06
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia in Children
    InterventionQuizartinib; Etoposide; Dexrazoxane; Mitoxantrone +5 more
    PhasePhase 2
    Registry statusRecruiting

  • Study of DPPG2-TSL-DOX Combined With Hyperthermia in Soft Tissue Sarcoma

    NCT05858710 · start 2023-04-19

    Registered record
    Registry ID
    NCT05858710
    Conditions
    Sarcoma, Soft Tissue
    Interventions
    DPPG2-TSL-DOX; Dexrazoxane
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-04-19
    Completion
    2025-05-28
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma, Soft Tissue
    InterventionDPPG2-TSL-DOX; Dexrazoxane
    PhasePhase 1
    Registry statusCompleted

  • Venetoclax Basket Trial for High Risk Hematologic Malignancies

    NCT05292664 · start 2023-03-29

    Registered record
    Registry ID
    NCT05292664
    Conditions
    Myelodysplastic Syndromes, de Novo; Myelodysplastic Syndromes, Secondary; Myelodysplastic Syndromes, Previously Treated; Treatment-Related Acute Myeloid Leukemia; Therapy-Related Myelodysplastic Syndrome; Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia With Failed Remission; Lymphoblastic Lymphoma, in Relapse; Lymphoblastic Lymphoma, Refractory; Acute Leukemia of Ambiguous Lineage in Relapse; Acute Leukemia of Ambiguous Lineage
    Interventions
    Venetoclax; Azacitidine; Cytarabine; Methotrexate; Hydrocortisone; Leucovorin; Dexamethasone; Vincristine; Doxorubicin; Dexrazoxane; Calaspargase Pegol; Erwinia asparaginase
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2023-03-29
    Completion
    2030-07-02
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelodysplastic Syndromes, de Novo; Myelodysplastic Syndromes, Secondary; Myelodysplastic Syndromes, Previously Treated; Treatment-Related Acute Myeloid Leukemia +7 more
    InterventionVenetoclax; Azacitidine; Cytarabine; Methotrexate +8 more
    PhasePhase 1
    Registry statusRecruiting

  • Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane

    NCT03930680 · start 2021-09-14

    Registered record
    Registry ID
    NCT03930680
    Conditions
    Degradation of Top2b and Top2a in Human by Dexrazoxane; Time Course and Degradation of Top2b in Human by Dexrazoxane; Effects of Dexrazoxane on Healthy Human
    Interventions
    Dexrazoxane
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-09-14
    Completion
    2025-06-11
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDegradation of Top2b and Top2a in Human by Dexrazoxane; Time Course and Degradation of Top2b in Human by Dexrazoxane; Effects of Dexrazoxane on Healthy Human
    InterventionDexrazoxane
    PhasePhase 1
    Registry statusCompleted

  • A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

    NCT04293562 · start 2020-07-21

    Registered record
    Registry ID
    NCT04293562
    Conditions
    Acute Myeloid Leukemia
    Interventions
    Allogeneic Hematopoietic Stem Cell Transplantation; Asparaginase Erwinia chrysanthemi; Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography; Cytarabine; Daunorubicin Hydrochloride; Dexrazoxane Hydrochloride; Etoposide; Fludeoxyglucose F-18; Gemtuzumab Ozogamicin; Gilteritinib Fumarate; Liposome-encapsulated Daunorubicin-Cytarabine; Magnetic Resonance Imaging; Methotrexate; Mitoxantrone Hydrochloride; Positron Emission Tomography; Questionnaire Administration; Therapeutic Hydrocortisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2020-07-21
    Completion
    2029-06-30
    Enrolment
    1,400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia
    InterventionAllogeneic Hematopoietic Stem Cell Transplantation; Asparaginase Erwinia chrysanthemi; Biospecimen Collection; Bone Marrow Aspiration +16 more
    PhasePhase 3
    Registry statusRecruiting

  • Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

    NCT03755804 · start 2018-12-12

    Registered record
    Registry ID
    NCT03755804
    Conditions
    Hodgkin Lymphoma
    Interventions
    bendamustine; Etoposide; Doxorubicin; Bleomycin; Vincristine; Vinblastine; Prednisone; Filgrastim; Brentuximab Vedotin; Cyclophosphamide; DTIC; Quality of Life Measurements; Radiotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2018-12-12
    Completion
    2028-07-01
    Enrolment
    232

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHodgkin Lymphoma
    Interventionbendamustine; Etoposide; Doxorubicin; Bleomycin +9 more
    PhasePhase 2
    Registry statusActive not recruiting

  • OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients

    NCT03698227 · start 2018-11-12

    Registered record
    Registry ID
    NCT03698227
    Conditions
    Advanced Soft Tissue Sarcoma
    Interventions
    Olaratumab; Dexrazoxane; Doxorubicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2018-11-12
    Completion
    2020-06-25
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Soft Tissue Sarcoma
    InterventionOlaratumab; Dexrazoxane; Doxorubicin
    PhasePhase 2
    Registry statusTerminated

  • Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

    NCT03126916 · start 2018-05-14

    Registered record
    Registry ID
    NCT03126916
    Conditions
    Ganglioneuroblastoma; Ganglioneuroblastoma, Nodular; Neuroblastoma
    Interventions
    Autologous Hematopoietic Stem Cell Transplantation; Biospecimen Collection; Bone Marrow Aspiration and Biopsy; Busulfan; Carboplatin; Cisplatin; Computed Tomography; Cyclophosphamide; Dexrazoxane Hydrochloride; Dinutuximab; Doxorubicin Hydrochloride; Echocardiography Test; Etoposide Phosphate; External Beam Radiation Therapy; Iobenguane I-123; Iobenguane I-131; Isotretinoin; Lorlatinib; Magnetic Resonance Imaging; Melphalan Hydrochloride; Multigated Acquisition Scan; Positron Emission Tomography; Sargramostim; Therapeutic Conventional Surgery; Thiotepa; Topotecan Hydrochloride; Vincristine Sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2018-05-14
    Completion
    2030-09-30
    Enrolment
    750

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGanglioneuroblastoma; Ganglioneuroblastoma, Nodular; Neuroblastoma
    InterventionAutologous Hematopoietic Stem Cell Transplantation; Biospecimen Collection; Bone Marrow Aspiration and Biopsy; Busulfan +23 more
    PhasePhase 3
    Registry statusRecruiting

  • Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

    NCT03007147 · start 2017-08-08

    Registered record
    Registry ID
    NCT03007147
    Conditions
    Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia; Mixed Phenotype Acute Leukemia; T Acute Lymphoblastic Leukemia
    Interventions
    Allogeneic Hematopoietic Stem Cell Transplantation; Calaspargase Pegol; Cyclophosphamide; Cytarabine; Daunorubicin Hydrochloride; Dexamethasone; Dexrazoxane Hydrochloride; Doxorubicin; Etoposide; Filgrastim; Ifosfamide; Imatinib Mesylate; Laboratory Biomarker Analysis; Leucovorin Calcium; Levoleucovorin; Mercaptopurine; Mercaptopurine; Methotrexate; Methylprednisolone; Pegaspargase; Prednisolone; Questionnaire Administration; Therapeutic Hydrocortisone; Thioguanine; Vincristine Sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2017-08-08
    Completion
    2027-08-14
    Enrolment
    352

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia; Mixed Phenotype Acute Leukemia; T Acute Lymphoblastic Leukemia
    InterventionAllogeneic Hematopoietic Stem Cell Transplantation; Calaspargase Pegol; Cyclophosphamide; Cytarabine +21 more
    PhasePhase 3
    Registry statusActive not recruiting

  • A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

    NCT03164057 · start 2017-06-15

    Registered record
    Registry ID
    NCT03164057
    Conditions
    Acute Myeloid Leukemia; Myelodysplastic Syndromes
    Interventions
    Azacitidine; Decitabine; Cytarabine; Daunorubicin; Etoposide; ITMHA; Idarubicin; Fludarabine; Mitoxantrone; Erwinia asparaginase; Sorafenib; G-CSF; Dexrazoxane; Stem Cell Transplant; Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2017-06-15
    Completion
    2027-06
    Enrolment
    206

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; Myelodysplastic Syndromes
    InterventionAzacitidine; Decitabine; Cytarabine; Daunorubicin +11 more
    PhasePhase 2
    Registry statusActive not recruiting